Showing results (1791-1800 of 2,008) with videos related to

Sort By:
Pageof 201
Journal of the American Chemical Society|June 30, 2025
A Molecular Glue Approach to Control the Half-Life of CRISPR-Based TechnologiesVedagopuram Sreekanth, Max Jan, Kevin T Zhao, et al.
Nature Medicine|February 16, 2023
Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in miceDaniel Reichart, Gregory A Newby, Hiroko Wakimoto, et al.
The Journal of Investigative Dermatology|May 19, 2024
Twin Prime Editing Mediated Exon Skipping/Reinsertion for Restored Collagen VII Expression in Recessive Dystrophic Epidermolysis BullosaBenjamin J Steinbeck, Xin D Gao, Amber N McElroy, et al.
JTCVS Open|April 10, 2026
Early post-lung transplant weight gain is associated with increased long-term recipient survivalYun Zhu Bai, Charles R Liu, Yan Yan, et al.
Zhonghua Yi Xue Za Zhi|July 23, 2018
[Impact of high-sensitivity C-reactive protein on outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation]Y Liu, Y Yao, X F Tang, et al.
Genes, Brain, and Behavior|November 30, 2012
Novel PRRT2 mutations in paroxysmal dyskinesia patients with variant inheritance and phenotypesX-R Liu, M Wu, N He, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|November 22, 2018
[Relationship between thrombolysis in myocardial infarction risk index and the severity of coronary artery lesions and long-term outcome in acute myocardial infarction patients undergoing percutaneous coronary intervention]Y Chen, Y Song, J J Xu, et al.
Nature Communications|August 15, 2023
Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivoYong Tao, Veronica Lamas, Wan Du, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|January 24, 2019
[Impact of coronary artery lesion calcification on the long-term outcome of patients with coronary heart disease after percutaneous coronary intervention]Y Zhang, L Song, Y Song, et al.
ESMO Open|July 26, 2024
Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trialsF-R Liu, X-L Wei, W-N Feng, et al.
Pageof 201